UnitedHealth confirms DOJ criminal probe two months after calling a report of one ‘irresponsible’

UnitedHealth Group (UNH) confirmed it is facing U.S. Department of Justice criminal and civil investigations into its Medicare practices, two months after initially dismissing reports of such a probe as 'irresponsible.' Despite the confirmation, which led to UNH shares falling 1.8% on Thursday, the company stated it proactively contacted the DOJ and does not expect to be charged, citing a strong compliance record and favorable independent audits. This development adds to UNH's stock performance challenges, with shares down 43.2% in 2025, making it the Dow's worst performer.

Analysis

UnitedHealth Group (UNH) has confirmed it is complying with a U.S. Department of Justice criminal and civil investigation into its Medicare practices, a significant reversal from its statement two months prior which labeled reports of such a probe 'deeply irresponsible.' This confirmation introduces a material legal and reputational overhang for the company. While management is taking a defensive posture by highlighting its 'proactive' outreach to the DOJ, its strong compliance history, and a favorable outcome in a prior civil case, the shift in disclosure raises governance concerns. The market's reaction, a 1.8% drop in the stock, adds to what is already a severe underperformance for UNH. The stock's 43.2% decline in 2025 makes it the worst performer in the Dow Jones Industrial Average, starkly contrasting with the DJIA's 5.4% gain and the Health Care Select Sector SPDR's (XLV) minor 0.7% slip, indicating the negative sentiment is highly company-specific. The launch of a third-party review of its own practices underscores the gravity of the situation, even as the company expresses confidence it will not face charges.

Key Decisions for Investors

• Investors should recognize that the confirmation of a DOJ criminal probe creates a significant legal and headline risk, which will likely act as a persistent overhang on the stock until a resolution is reached.
• The company's pivot from dismissing the investigation as 'irresponsible' to confirming compliance raises governance questions that warrant a cautious approach, despite management's claims of a strong compliance record.
• Given the stock's 43.2% year-to-date decline, it is crucial to weigh the potential for a valuation recovery against the unquantifiable risk of financial penalties or operational changes stemming from the probe.
• Closely monitor for any disclosures related to the DOJ investigation or the findings of the company's internal third-party review, as these will be the primary catalysts determining the stock's direction.